Background: Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis (AS) effectively. However, no study systematically investigated the efficacy and safety of etoricoxib for patients with AS. In this systematic review, we will assess the efficacy and safety of etoricoxib for AS.
Methods: The following electronic databases will be searched from inception to the February 1, 2019: Cochrane Library, Embase, PubMed, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Chinese Scientific Journal Database. This study will include randomized controlled trials that explore the efficacy and safety of etoricoxib for AS. The primary outcome is pain intensity, as measured by any pain scales, such as Numerical Rating Scale. The secondary outcomes consist of AS function, as measured by Bath Ankylosing Spondylitis Functional Index, or other tools; quality of life, as assessed by Ankylosing Spondylitis Quality of Life questionnaire or any other relevant instruments; as well as adverse events. Two authors will independently carry out the study selection, data extraction, and risk of bias assessment. Statistical analysis will be performed by using RevMan 5.3 software.
Results: This systematic review will provide a detailed summary of present evidence related to the efficacy and safety of etoricoxib for patients with AS.
Conclusion: The results of this study may provide management guidance for AS treated by etoricoxib.
Dissemination And Ethics: This systematic review dose not needs ethical approval, because it will not analyze individual patient data. The findings of this study are expected to publish through a peer-reviewed journal.
Systematic Review Registration: CRD42019124768.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485787 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000015155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploration of molecular biomarkers in ankylosing spondylitis transcriptomics.
Front Immunol
December 2024
Research Center of Hyperuricemia and Gout, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Background: Inflammation of the spine and sacroiliac joints is a hallmark of the chronic, progressive inflammatory illness known as ankylosing spondylitis (AS). The insidious onset and non-specific early symptoms of AS often lead to delays in diagnosis and treatment, which may result in the onset of disability. It is therefore imperative to identify new biomarkers.
View Article and Find Full Text PDFFive Cases of Non-radiographic Spondyloarthritis (nr-SpA) of Patients from a Tertiary Care Center in the Philippines: A Case Series.
Acta Med Philipp
November 2024
Department of Medicine, Makati Medical Center.
Axial Spondyloarthritis (SpA) is a chronic inflammatory disease of the spine associated with the gene HLA-B27. Non-radiographic spondyloarthritis (nr-SpA), an early stage of axial SpA often goes unrecognized in many settings including the Philippines. We describe five Filipinos from a tertiary health care facility who fulfill the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria for non-radiographic SpA with the aim of increasing awareness of this disease in the Philippines.
View Article and Find Full Text PDFFormulation, Characterization, and Cytotoxic Effect of Indomethacin-Loaded Nanoparticles.
Antiinflamm Antiallergy Agents Med Chem
December 2024
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
Background: Indomethacin (IND), classified as class 2 in the Biopharmaceutical Classification System (BCS), has emerged as an anti-inflammatory agent with low solubility and high permeability. Widely used in the treatment of various diseases, such as rheumatoid arthritis and ankylosing spondylitis, this drug is well-known for its adverse effects, particularly in the stomach, and a short biological half-life, which is around 1.5-2 hours.
View Article and Find Full Text PDFCelecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.
BMB Rep
January 2025
Division of Rheumatology, Regional Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon 35015, Korea.
Spondyloarthritis (SpA) is a chronic inflammatory disease that leads to ankylosis of the axial skeleton. Celecoxib (cyclooxygenase-2 inhibitor, COX-2i) inhibited radiographic progression in a clinical study of SpA, but in the following study, diclofenac (COX-2 non-selective) failed to show that inhibition. Our study aimed to investigate whether nonsteroidal anti-inflammatory drugs (NSAIDs) inhibited bone progression in SpA, and whether celecoxib had a unique function (independent of the COX-inhibitor), compared with the other NSAIDs.
View Article and Find Full Text PDFEffectiveness of education programs on axSpA patients: a systematic review of randomized controlled trials.
ARP Rheumatol
January 2024
Unidade Local Saúde de Lisboa Ocidental, Hospital de Egas Moniz.
Introduction: The current standard of care of patients with spondyloarthritis (SpA), in addition to pharmacological treatment, includes regular exercise and patient education.(1) The primary goal of this systematic literature review (SLR) is to update the evidence of the effectiveness of education programs for patients with axial SpA (axSpA).
Methods: We systematically searched three databases, PubMed, Embase and Web of Science Core Collection, from January 2000 to June 2023, using the following terms: "patient education", "patient counselling", "patient teaching", "patient engaging", "patient empowerment", "health education", "spondyloarthritis", "spondyloarthropaties", "spondylitis" and "ankylosing spondylitis".
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!